clinical trial · NCT06305559
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
NewAmsterdam Pharma·phase3·active not recruiting·n = 300
LipidemiaCoronary Artery DiseasePlaque, Atheroscleroticobicetrapib 10 mg + ezetimibe 10 mg FDC dailyPlacebo
brief summary
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).
started
May 16, 2024
primary completion
Nov 1, 2027
completion
Feb 1, 2028
last updated
Apr 9, 2026
official title
A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol